Overexpression of miR-145–5p Inhibits Proliferation of Prostate Cancer Cells and Reduces SOX2 Expression

REFERENCES

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65(1):5–29.
   PubMed Web of Science ®Google Scholar
• Bhatnagar N, Li X, Padi SK, Zhang Q, Tang MS, Guo B. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 2010;1:e105.
   PubMed Web of Science ®Google Scholar
• Seven M, Karatas OF, Duz MB, Ozen M. The role of miRNAs in cancer: From pathogenesis to therapeutic implications. Future Oncol 2014;10(6):1027–1048.
   PubMed Web of Science ®Google Scholar
• Sevli S, Uzumcu A, Solak M, Ittmann M, Ozen M. The function of microRNAs, small but potent molecules, in human prostate cancer. Prostate Cancer Prostatic Dis 2010;13(3):208–217.
   PubMed Web of Science ®Google Scholar
• Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: Tools for microRNA genomics. Nucleic Acids Res 2008;36(Database issue):D154–D158.
   PubMed Web of Science ®Google Scholar
• Majid S, Dar AA, Saini S, Yamamura S, Hirata H, Tanaka Y, Deng G, Dahiya R. MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer 2010;116(24):5637–5649.
   PubMed Web of Science ®Google Scholar
• Shi XB, Tepper CG, White RW. MicroRNAs and prostate cancer. J Cell Mol Med 2008;12(5A):1456–1465.
   PubMed Web of Science ®Google Scholar
• Voorhoeve PM, Agami R. Classifying microRNAs in cancer: The good, the bad and the ugly. Biochim Biophys Acta 2007; 1775(2):274–282.
   PubMed Web of Science ®Google Scholar
• Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell'Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, Negrini M, Croce CM. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 2004;101(32):11755–11760.
   PubMed Web of Science ®Google Scholar
• Chen X, Gong J, Zeng H, Chen N, Huang R, Huang Y, Nie L, Xu M, Xia J, Zhao F, Meng W, Zhou Q. MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. Cancer Res 2010;70(7):2728–2738.
   PubMed Web of Science ®Google Scholar
• Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008;27(12):1788–1793.
   PubMed Web of Science ®Google Scholar
• Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007;67(13):6130–6135.
   PubMed Web of Science ®Google Scholar
• Suh SO, Chen Y, Zaman MS, Hirata H, Yamamura S, Shahryari V, Liu J, Tabatabai ZL, Kakar S, Deng G, Tanaka Y, Dahiya R. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis 2011;32 (5):772–778.
   PubMed Web of Science ®Google Scholar
• Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO, Saini S, Majid S, Liu J, Khatri G, Tanaka Y, Dahiya R. The functional significance of microRNA-145 in prostate cancer. Br J Cancer 2011;103(2):256–264.
   Web of Science ®Google Scholar
• Fuse M, Nohata N, Kojima S, Sakamoto S, Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, Naya Y, Ichikawa T, Seki N. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol 38(4):1093–1101.
   PubMed Web of Science ®Google Scholar
• Kojima S, Enokida H, Yoshino H, Itesako T, Chiyomaru T, Kinoshita T, Fuse M, Nishikawa R, Goto Y, Naya Y, Nakagawa M, Seki N. The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J Hum Genet 2014;59(2):78–87.
   PubMed Web of Science ®Google Scholar
• Bylund M, Andersson E, Novitch BG, Muhr J. Vertebrate neurogenesis is counteracted by Sox1–3 activity. Nat Neurosci 2003;6(11):1162–1168.
   PubMed Web of Science ®Google Scholar
• Bae KM, Su Z, Frye C, McClellan S, Allan RW, Andrejewski JT, Kelley V, Jorgensen M, Steindler DA, Vieweg J, Siemann DW. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol 2010;183(5):2045–2053.
   PubMed Web of Science ®Google Scholar
• Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007;67(10):4807–4815.
   PubMed Web of Science ®Google Scholar
• Kasper S. Exploring the origins of the normal prostate and prostate cancer stem cell. Stem Cell Rev 2008;4(3):193–201.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Wang G, Wang J, Sadar MD. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. Cancer Res 2008;68(23):9918–9927.
   PubMed Web of Science ®Google Scholar
• Byun J, Logothetis CJ, Gorlov IP. Housekeeping genes in prostate tumorigenesis. Int J Cancer 2009;125(11):2603–2608.
   PubMed Web of Science ®Google Scholar
• Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007;7:64.
   PubMed Web of Science ®Google Scholar
• Thomsen MK, Francis JC, Swain A. The role of Sox9 in prostate development. Differentiation 2008;76(6):728–735.
   PubMed Web of Science ®Google Scholar
• Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009;137 (4):647–658.
   PubMed Web of Science ®Google Scholar
• Wang L, Tang H, Thayanithy V, Subramanian S, Oberg AL, Cunningham JM, Cerhan JR, Steer CJ, Thibodeau SN. Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 2009;69(24):9490–9497.
   PubMed Web of Science ®Google Scholar
• Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, Sun L, Yang X, Wang Y, Zhang Y, Shang Y. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 2008;283(26):17969–17978.
   PubMed Web of Science ®Google Scholar
• Jia X, Li X, Xu Y, Zhang S, Mou W, Liu Y, Lv D, Liu CH, Tan X, Xiang R, Li N. SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol 2011;3(4):230–238.
   PubMed Web of Science ®Google Scholar
• Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, Miki C, Kusunoki M. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 2009;16(12):3488–3498.
   PubMed Web of Science ®Google Scholar
• Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: Targets and expression. Nucleic Acids Res 2008;36(Database issue):D149–D153.
   PubMed Web of Science ®Google Scholar
• Griffiths-Jones S. miRBase: microRNA sequences and annotation. Current protocols in bioinformatics/editoral board, Andreas D Baxevanis [et al]. 2010;12:(12 9) 1–0.
   Google Scholar
• Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120(1): 15–20.
   PubMed Web of Science ®Google Scholar
• Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. miRecords: An integrated resource for microRNA-target interactions. Nucleic Acids Res 2009;37(Database issue):D105–D110.
   PubMed Web of Science ®Google Scholar
• Papadopoulos GL, Reczko M, Simossis VA, Sethupathy P, Hatzigeorgiou AG. The database of experimentally supported targets: A functional update of TarBase. Nucleic Acids Res 2009;37(Database issue):D155–8.
   PubMed Web of Science ®Google Scholar
• Wang X. miRDB: A microRNA target prediction and functional annotation database with a wiki interface. RNA 2008;14(6):1012–1017.
   PubMed Web of Science ®Google Scholar